NEW YORK (GenomeWeb News) — Compugen today reported revenue for the fourth quarter as R&D spending increased 20 percent and net loss widened 12 percent.
 
Total receipts for the three months ended Dec. 31, 2006, were $10,000 compared with zero revenue one year ago.
 
Compugen said R&D spending in the quarter rose to $2.9 million from $2.4 million year over year.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.